RoslinCT and Ayrmid Pharma Ltd. announce their intent to enter into a strategic partnership to manufacture FDA approved cell therapy Omisirge® (omidubicel-onlv)

March 11 2025, Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. 

It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cells’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that the technology transfer and commercial manufacturing will take place in RoslinCT’s state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA. 

 “As part of our global dual sourcing strategy we are delighted to announce that we intend to work with RoslinCT on the technology transfer of Omisirge to their state-of-the-art facility in Hopkinton, MA,” said Dr Joe Wiley, Chief Executive Officer of Ayrmid. He added:

This key strategic move will allow Gamida Cell to source Omisirge for our patients from both our internal manufacturing capability and RoslinCT.

“The dynamic interactions between the two teams are very productive and we look forward to working with the Aymrid Pharma Ltd. and Gamida Cell Inc. teams to support the production of this innovative product for their patients in the United States,” said Peter Coleman, Chief Executive Officer of RoslinCT.  He added, “We’re delighted about the intent to partner with Gamida Cell and add this product to the portfolio of commercial products manufactured at RoslinCT.”